Physician profile
Pavan Tummala
NPI 1407111313
$10,490.41
in general payments reported to CMS, 2019-2025
69 companies · $2,259 in 2025
The $2,259 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $973 · 2021: $992 · 2022: $2,422 · 2023: $1,052 · 2024: $1,981 · 2025: $2,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,291.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,831.77 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Pfizer INC. | $889.65 | 2019-2025 | |
| Livanova USA, INC. | $690.22 | 2019-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $542.89 | 2019-2022 | |
| Ucb, INC. | $502.35 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Eisai INC. | $420.16 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $351.49 | 2020-2025 | Daybue, Nuplazid |
| Emd Serono, INC. | $340.87 | 2019-2025 | Mavenclad |
| Argenx US, INC. | $309.18 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $292.65 | 2019-2023 | |
| Biogen, INC. | $283.44 | 2020-2025 | Vumerity, Skyclarys, Tysabri |
| Jazz Pharmaceuticals INC. | $271.90 | 2019-2025 | |
| Sk Life Science, INC. | $263.12 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $210.60 | 2019-2025 | Crexont |
| Teva Pharmaceuticals USA, INC. | $205.54 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 68 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Tummala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.